GLP-1 and PCOS: what the 'non-scale victory' narrative gets right and wrong

What did @catreaamcknight actually say?

Honestly, not much that's medically analyzable. The transcript is almost entirely motivational and spiritual in nature: "God will work on" your situation, "things are coming together for you this year," and "things are working out in your face." There are no dosing claims, no weight loss statistics, no physiological assertions about GLP-1 medications.

The video is a paid partnership with Mochi Health (disclosed via the #AD and #mochipartner hashtags, which is legally required and credit where it's due for transparency). The PCOS and GLP-1 hashtags tell us the intended audience: people with polycystic ovary syndrome who are considering or currently using GLP-1 receptor agonists for weight management. But the spoken content itself is a faith-based affirmation, not a medical tutorial. The gap between what the hashtags promise and what the creator actually says is the real story here.

Does the science back this up?

There is no scientific claim in the transcript to evaluate directly. What we can assess is the broader context the video operates in: GLP-1 medications and PCOS. On that front, the emerging evidence is genuinely interesting, though not yet definitive.

GLP-1 receptor agonists like semaglutide and tirzepatide have shown real metabolic benefits in people with PCOS. A 2023 randomized controlled trial by Jensterle et al. published in Diabetes, Obesity and Metabolism found that semaglutide produced significant reductions in body weight, androgen levels, and menstrual irregularity in women with PCOS compared to placebo. Tirzepatide, which targets both GLP-1 and GIP receptors, showed similarly promising results in insulin-resistant PCOS patients in a 2023 case series by Alyousif et al. in Frontiers in Endocrinology. These are not cures. They are tools with a growing evidence base in a population that has historically been underserved by pharmacological options.

The motivational framing, "enjoy your current season" and "love yourself no matter what," is not science, but it is also not wrong. Self-compassion during a weight loss journey is associated with better adherence outcomes (Mantzios and Wilson, 2015, Journal of Health Psychology).

What did they get wrong (or right)?

Nothing in the transcript is medically inaccurate, because the transcript makes no medical claims. That is simultaneously the video's strength and its weakness. It does not mislead anyone about how semaglutide works, what doses to take, or what results to expect. That's responsible.

What it does do is use medical hashtags, PCOS and GLP-1, to funnel a specific patient population toward a paid telehealth partner while delivering content that is entirely emotional. That is a marketing strategy, not a health education one. Viewers who clicked hoping to learn something about GLP-1s and PCOS got a spiritual pep talk instead.

To be fair, the #AD disclosure is present and clearly labeled. Mochi Health is a legitimate regulated telehealth platform. The creator is not making false efficacy claims or pushing unverified dosing protocols. In a TikTok ecosystem full of creators claiming semaglutide will reverse every chronic condition in 90 days, this video is comparatively benign.

What should you actually know?

If you have PCOS and you are researching GLP-1 medications, here is what the actual evidence says. GLP-1 agonists can help with insulin resistance, a core driver of PCOS symptoms, and some patients see improvements in menstrual regularity and androgen levels alongside weight changes (Jensterle et al., 2023). These are prescription medications with real side effect profiles including nausea, vomiting, and, in rare cases, pancreatitis.

Compounded versions of semaglutide or tirzepatide are not the same as brand-name Wegovy, Ozempic, Mounjaro, or Zepbound. The FDA has issued warnings about compounded GLP-1 products, and clinical equivalency cannot be assumed. If a telehealth platform is prescribing you a compounded peptide, that is a separate risk conversation you need to have with a licensed prescriber, not a TikTok creator.

The "compare your journey to no one else's" message is not bad advice for people navigating a chronic condition. But motivational content with a sponsored telehealth link is not a substitute for individualized medical evaluation. Start with a doctor who knows your labs, your history, and your goals.